Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6 enzyme, is associated with substrate-specific altered clearance of multiple drugs.
to reach for the next cigarette. Hence, polymorphisms in CYP2A6 causing slower nicotine metabolism are also associated with reduced cigarette consumption and disease risk in multiple populations. [4] [5] [6] [7] Nicotine is also metabolized via two other major pathways: glucuronidation by UGT2B10, and oxidation to nicotine-N-oxide by the flavin-containing monooxygenases (FMOs) . Variation in FMO3 is associated with altered hepatic nicotine metabolism. 8 CYP2B6 is a minor contributor to hepatic nicotine metabolism with a K m approximately 10-fold higher than that of CYP2A6. 9 Genetic variation in the CYP2B6 locus has a small but clinically insignificant influence on in vivo nicotine clearance in most subjects, 10, 11 but may be important in CYP2A6 slow metabolizers.
CYP2B6 has also been reported to be expressed in human brain tissue, 12 unlike CYP2A6, and it has therefore been proposed that genetic variation affecting the CYP2B6 enzyme might play a significant role in nicotine-related phenotypes. 13 CYP2B6 is highly polymorphic, and common haplotypes, especially CYP2B6*6 and *9, containing 516G>T (Q172H, minor allele frequency 26% in European Americans, 37% in African Americans (http://evs.gs.washing ton.edu/EVS/)) are associated with clinically significantly altered pharmacokinetics for different substrates, relative to the reference allele. [14] [15] [16] [17] [18] [19] Because the effects of CYP2B6 polymorphisms on CYP2B6 activity is substrate-specific, activities of different CYP2B6
isoforms cannot be assumed for untested substrates, such as nicotine. Therefore, we have expressed polymorphic CYP2B6 enzymes and measured their nicotine metabolism activity in vitro. We further attempted to measure cytochrome P450-mediated nicotine metabolism in human brain microsomes, where FMO activity was previously demonstrated, 8, 20 using nicotine and other CYP2B6 probe substrates.
| MATERIALS AND METHODS
CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b 5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described. 17, 21 Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymor- 
| Substrate metabolism
All incubations were carried out in 96-well PCR plates in 50 μL total volume at 37°C, as previously described. methadone and processed and analyzed as previously described. 21, 27 In brief, methadone was from the National Institute on Drug Abuse (Bethesda, MD); all other reagents were purchased from SigmaAldrich. Reactions were quenched with 40 μl 20% trichloroacetic acid containing internal standard (d3-EDDP), and centrifuged for 5 minutes at 2500g; the supernatant was processed by solid phase extraction as previously described, 28, 29 except that for Strata-X-C 33-μm, 30 mg/well plates (Phenomenex, Torrance, CA) were used.
Analysis was performed on a Sunfire C18 column (2.1 × 50 mm, Ketamine incubations were performed with 80 μmol L −1 ketamine, and processed and analyzed as previously described 17 In brief, the reactions were quenched with 20% trichloroacetic acid containing norketamine-d4. The plate was centrifuged at 900 g for 5 minutes and the supernatant was subjected to solid phase extraction. 30 Analytes were eluted with methanol and evaporated to dry- re-equilibrated to initial conditions between 6.5 and 8.5 minutes.
Under these conditions, the retention times for nicotine iminium and nornicotine (a minor CYP2B6 nicotine metabolite 9 ) were 2.5 and 3.7 minutes, respectively; for cis and trans nicotine-N-oxide, they 
| Statistical analysis
Michaelis-Menten parameters for recombinant enzyme experiments were determined by nonlinear regression using SigmaPlot (Systat Software, San Jose, CA).
| RESULTS

| Nicotine oxidation by variant recombinant
CYP2B6 enzymes
Nine recombinant versions of the CYP2B6 enzymes, representing common CYP2B6 haplotypes, were expressed to assess their relative nicotine metabolism activities. Two nicotine metabolites were measured, nicotine iminium ion and nornicotine, with K m and V max parameters determined for both metabolites for each variant (Table 1) . Our results confirm the role of CYP2B6 in nornicotine formation. 9 As expected, the activity of the most common variant enzyme, CYP2B6.6, was lower than the reference allele enzyme, CYP2B6.1, regarding both nicotine iminum (Cl int = 1.9 vs 3.2 μL
) and nornicotine (Cl int = 0.5 vs 1.0 μL min
Variation in CYP2B6 affects enzyme activity differently depending on substrate, which may include differences between isomers of the same molecule. Nicotine occurs in two isomers, though approximately 99% of naturally occurring nicotine derived from tobacco and other plants is the (S) isomer. In order to determine if effects on CYP2B6 nicotine metabolism activity were also enantiomer-specific, incubations with four CYP2B6 haplotypes were repeated with (R)-nicotine ( Table 2) . K m and V max parameters were different for (R)-nicotine and (S)-nicotine, but differences between CYP2B6 variants appear consistent, that is, the activity of CYP2B6.6, was again lower than the reference allele enzyme for nicotine iminum (Cl int = 0.8 vs 
| DISCUSSION
Extensive evidence demonstrates that functional variation in cytochrome P450 genes can significantly affect the metabolism of many small molecules including pharmaceuticals and toxins. Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substrate-dependent manner, 15, 16, 19, 22, 23, [32] [33] [34] and thus it is important to evaluate these enzyme variants for any CYP2B6
substrate. Here, we demonstrate how these common variants also affect nicotine metabolism in vitro. The differences we report, both for (S)-nicotine and (R)-nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. Because (S)-nicotine is the common naturally occurring form of nicotine relevant to smoking behavior, experiments with (R)-nicotine were only performed to explore substrate specificity and stereoselectivity. The activities of the nine enzyme variants also differed with regard to the relative metabolite ratios of (S)-nicotine iminium and (S)-nornicotine. The differences in this ratio demonstrate altered regioselectivity associated with each polymorphism, that is, changes in the activity of each enzyme isoform depend on which region of the substrate molecule the enzyme oxidizes, 35 resulting in the formation of nicotine iminum vs nornicotine.
Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate. 14, 21, 22 This demonstrates that the K262R amino acid change can partially compensate for the Q172H loss-of-function, depending on substrate, and we find this to be the case for nicotine as well. CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo. 16, 33 However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity. 10,36,37 CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 34 We previously demonstrated that common CYP2B6 haplotypes, including missense variants and noncoding variants that affect gene splicing, are associated with differences in in vivo nicotine metabolism. 10 However, the small contribution of CYP2B6 to hepatic nicotine metabolism 38 is unlikely to influence smoking behaviors.
CYP2B6 mRNA expression has been reported in human brain, 12 although direct evidence of CYP2B6 activity in brain tissue was not previously demonstrated. It has therefore been suggested that genetically determined variation in CYP2B6 activity in extrahepatic tissues might influence smoking behavior by altering local nicotine levels in the brain. 13 We recently demonstrated nicotine-N-oxidation by flavin-containing monoxygenases in microsomes prepared from human brain. 8 This provided an opportunity to further investigate possible cytochrome P450-related nicotine metabolism in postmortem samples known to retain detectable microsomal enzyme activity. Given the difficulty of obtaining postmortem human brain material, it was important to have a positive control for tissue quality. Postmortem intervals before initial freezing were typically 12 hours or more, and FMO activity is also subject to degradation at room temperature and following repeated freeze-thawing.
Interestingly, we found nicotine iminium ion produced in the presence of human brain microsomes (nornicotine was not detected), but the mechanism of this weak activity was obscure. It is independent of the cofactor NADPH and not inhibited by either carbon monoxide or NADP, though the activity was abolished by heat treatment of the microsomes. Meanwhile, the production of nicotine-N-oxide in the same incubations required NADPH and was inhibited by carbon monoxide, NADP, and heat treatment, as expected. We therefore conclude that the iminium ion detected was not due to cytochrome In summary, we conclude that nicotine metabolism by CYP2B6 is stereoselective, and common polymorphisms in CYP2B6 significantly influence the oxidation of both (S) and (R)-nicotine to nicotine iminium and nornicotine. However, the small contribution of CYP2B6 to nicotine metabolism in the liver, and its undetectable activity in human brain tissue, make it highly unlikely that this genetic variation influences complex smoking behaviors. 
